What do people know about Diamyd and have any people or their children been involved in trials?
As a company they seem to be doing well but how far along is the product?
Thanks in advance!!
Hi Emily, Here’s a link about Diamyd: http://diamyd.blogspot.com/2009/03/trialnet-starts-trial-using-diamyd.html
It says in part: “Trialnet will start the Diamyd Phase II trial at 15 clinics in the US.
This study will include 126 patients and add to the data planned to be received by the Phase III trials currently ongoing in the US and Europe, and the Combination trial mentioned earlier also supported by the NIH/NIDDK.”
Very far along, Diamyd is one of the 3 drugs that is in phase 3 trials for new onset T1. And there are 900+ people (including children) participating in the US and all over Europe
Clinical trials for new onset
http://clinicaltrials.gov/ct2/show/record/NCT00529399?term=diamyd&a…
http://clinicaltrials.gov/ct2/show/NCT00723411?term=diamyd&rank=1
http://clinicaltrials.gov/ct2/show/NCT00751842?term=diamyd&rank=4
In existing T1s together with beta regeneration
http://clinicaltrials.gov/ct2/show/NCT00837759?term=diamyd&rank=5
There was a Swedish article too about a teen who received this a couple of years ago and her remaining beta cells have been saved making her D management much easier. I’ll post it if I can find it.
Diamyd has also had excellent results with LADA
http://finance.yahoo.com/news/Diamydr-Study-Published-in-pz-1511463…
And this year they are starting preventative vaccine studies in children/adults who are at risk for developing T1
Here is a press article on the subject. I.m so glad for the predisposed people to have this opportunity to preventitive drugs… So sorry it’s after our time…
I just received this press release (from last December) that talks about their FDA approval.
http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467307
Diamyd® vaccine approved for studies in children down to 3 years of age in the US
Diamyd Medical reports today that the United States Food and Drug Administration (FDA) has approved the experimental use of Diamyd® vaccine in children as young as 3 years of age in the TrialNet GAD study, enrolling 126 new onset type 1 diabetes patients in North America.
The TrialNet GAD study, conducted by an international network of leading pediatric and adult endocrinologists and immunologists, has previously enrolled new onset type 1 diabetes patients from 16 to 45 years of age but is now allowed by the FDA to enroll and administer the Diamyd® vaccine to children as young as 3 years of age.
“This is very encouraging news,” says Elisabeth Lindner, CEO and President at Diamyd Medical. “The approval to enroll small children in the TrialNet study is based on an FDA review of safety data from our ongoing Phase III trials and further supports that the Diamyd® vaccine’s safety profile is strong.”
The TrialNet study is a double-blind, randomized, placebo-controlled trial, which aims to enroll a total of 126 new onset type 1 diabetes patients at 16 TrialNet sites in the US and Canada. One third of the participants will receive 3 injections with the Diamyd® vaccine, one third will receive 2 injections with the Diamyd® vaccine and one third will receive placebo (inactive drug). The purpose of the study is to determine whether the Diamyd® vaccine will preserve the body’s ability to make its own insulin to help control blood sugar.
The trial also includes extensive immunological studies to clarify the mechanism of action of Diamyd® and to evaluate the correlation between the clinical and immunological outcomes of Diamyd® treatment in new onset type 1 diabetes patients.
Diamyd Medical has approved the protocol and has executed a Clinical Trial Agreement with the National Institute of Diabetes and Digestive and Kidney Diseases, part of the US National Institutes of Health, to supply clinical-grade material (i.e. Diamyd® and placebo) for this trial. TrialNet is sponsored by the National Institutes of Health and supported by Juvenile Diabetes Research Foundation International and the American Diabetes Association.
For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)
Phone: +46 8 661 0026